EYEN
- Eyenovia, Inc.
()
Overview
Company Summary
Eyenovia, Inc. is a pharmaceutical company that focuses on developing and commercializing innovative treatments for various eye conditions and diseases. The company specializes in utilizing advanced technology to create micro-dose therapeutics that are administered through microdroplets, providing more precise and targeted delivery to the eye.
Eyenovia's flagship product is the MicroPine, which is being developed for the treatment of progressive myopia, commonly known as nearsightedness. Myopia is a condition where the eye grows too long, causing blurred distance vision. The MicroPine solution aims to slow down the progression of myopia in children and adolescents. By utilizing its high-precision microdosing technology, Eyenovia aims to improve treatment outcomes, reduce side effects, and enhance patient convenience.
Additionally, Eyenovia is actively engaging in the development of other ophthalmic products. The company is working on MicroLatan, a microdose formulation of latanoprost, intended for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. MicroLatan seeks to offer improved ease of use, tolerability, and potentially enhanced adherence for patients.
Eyenovia's innovative approach to ophthalmic drug delivery sets it apart in the industry. By focusing on microdosing technology, the company aims to address current limitations and challenges in eye treatments, ultimately improving patients' lives and providing healthcare professionals with more effective and efficient solutions.